Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2018
Price : $35 *
At a glance
- Drugs Cabiralizumab (Primary) ; Nivolumab (Primary) ; Urelumab (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Acronyms C4-MOSART
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.
- 16 Feb 2018 New trial record